Loading...
•
Jun 30, 2024
IDEAYA Q2 2024 Earnings Report
Announced financial results for the second quarter ended June 30, 2024 and provided a business update.
Key Takeaways
IDEAYA Biosciences reported $952.7 million in cash, cash equivalents and marketable securities as of June 30, 2024. Significant progress was made advancing four potential first-in-class precision medicine oncology clinical programs. Preliminary clinical proof of concept data was presented for IDE397 monotherapy in MTAP-deletion urothelial and lung cancer.
Darovasertib achieved triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM and >50 patients enrolled in Phase 2 neoadjuvant UM study
Demonstrated preliminary proof-of-concept for IDE397 in MTAP urothelial and lung cancer with 1 PR awaiting confirmation confirmed and 1 additional PR still awaiting confirmation
IDEAYA financially budgeted to support its obligations for target IDE397 / AMG 193 clinical combination expansion in NSCLC in consultation with Amgen
IDEAYA plans to host an Investor R&D Day in Q4 2024
Forward Guidance
IDEAYA is targeting several milestones in the second half of 2024 across its clinical programs.
Positive Outlook
- Targeting Phase 2 neoadjuvant UM data update in H2'24
- Targeting initial IDE161 Ph 1/2 expansion in H2'24
- Targeting Phase 1 FPI for IDE161 in combination with KEYTRUDA in endometrial cancer in H2'24
- Targeting Werner IND in H2'24
- Targeting MTAP and KAT6 pathway DCs in H2'24
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...